SLGL Sol-Gel Technologies
Filed: 28 Jun 21, 8:14am
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
SOL-GEL TECHNOLOGIES LTD.
(Translation of registrant’s name into English)
For the month of May 2021
7 Golda Meir Street
Ness Ziona 7403650, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On May 13, 2021, Sol-Gel Technologies Ltd. (the “Company”) issued two press releases: (i) a press release announcing exclusive licenses with Galderma for the commercialization of EPSOLAY® and TWYNEO® in the United States and (ii) a press release announcing the Company’s pipeline update and future development plans.
Attached hereto are the following exhibits:
This 6-K and Exhibits 99.1 and 99.2 are hereby incorporated by reference into the Company's Registration Statement on Form S-8 (Registration No. 333-223915) and its Registration Statement on Form F-3 (Registration No. 333-230564).
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|SOL-GEL TECHNOLOGIES LTD.|
|Date: June 28, 2021||By:||/s/ Gilad Mamok|
|Chief Financial Officer|